Menu Search
Equities

electroCore, Inc.

  • Add to watchlist
  • Add to portfolio
  • Add an alert
43E0:MUN

electroCore, Inc.

Actions
  • Price (EUR)4.52
  • Today's Change0.000 / 0.00%
  • Shares traded250.00
  • 1 Year change-72.10%
  • Beta0.5495
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.

  • Revenue in USD (TTM)29.84m
  • Net income in USD-14.16m
  • Incorporated2005
  • Employees73.00
  • Location
    electroCore, Inc.200 FORGE WAY, SUITE 205ROCKAWAY 07866United StatesUSA
  • Phone+1 (973) 290-0097
  • Fax+1 (973) 290-9171
  • Websitehttps://www.electrocore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.